Advances of Sirolimus in the Treatment of Patients with Autoimmune Cytopenia---Review.
10.19746/j.cnki.issn.1009-2137.2021.05.048
- Author:
Ya-Ru WANG
1
;
Yan-Ping MA
2
,
3
;
Xiao-Qi QIN
1
Author Information
1. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China.
2. Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China E-mail: myanp18@
3. com.
- Publication Type:Review
- MeSH:
Humans;
Immunosuppressive Agents;
Sirolimus;
T-Lymphocytes, Regulatory;
Thrombocytopenia
- From:
Journal of Experimental Hematology
2021;29(5):1667-1670
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune cytopenia is a general term for all hemocytopenia diseases caused by humoral or cellular immunity abnormalities, and its common immune mechanism determines the importance of immunosuppressive therapy. Sirolimus, as an immunosuppressant against of mTOR, induces immune tolerance by adjusting Treg cells, which has application prospect in the treatment of refractory autoimmune cytopenia. This article reviews the mechanism, application, and possible adverse reactions of sirolimus in the treatment of idiopathic autoimmune cytopenia.
